CardioPulmonary Vascular Biology COBRE

心肺血管生物学 COBRE

• 批准号: 10630735
• 负责人: Gaurav Choudhary
• 金额: $ 91.35万
• 依托单位: OCEAN STATE RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630735
• 关键词: 2019-nCoV; Advisory Committees; Affect; Area; Award; Biology; Blood Vessels; COVID-19 pandemic; Cardiopulmonary; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Cell Separation; Centers of Research Excellence; Collaborations; Communities; Coronary Arteriosclerosis; Data; Development; Discipline; Disease; Educational workshop; Feedback; Fostering; Funding; Goals; Growth; Home; Human; Infection; Infrastructure; Institution; Investigation; Learning; Legal patent; Lung; Lung diseases; Manuscripts; Mission; Mitochondria; Morbidity - disease rate; Organ; Pathogenesis; Phase; Pilot Projects; Prevention; Productivity; Prognosis; Publishing; Research; Research Personnel; Research Project Grants; Resources; Respiratory Disease; Rhode Island; Scientist; Services; Structure; Vascular Diseases; Virus; Vision; career; catalyst; combat; comorbidity; effective therapy; in vivo imaging; mortality; prevent; programs; pulmonary vascular disorder; respiratory

The vision of the CardioPulmonary Vascular Biology (CPVB) COBRE program is to develop effective approaches to prevent and treat vascular diseases affecting the pulmonary and cardiovascular systems through better understanding of disease mechanisms. This will be accomplished by serving as an interdisciplinary center which promotes collaborative research and provides excellent technical support and resources to investigators. The overall mission of the CPVB COBRE program has been to build the human and technical infrastructure and services that serve as catalysts to increase CPVB research in the state. Cardiovascular and pulmonary diseases are among the leading causes of morbidity and mortality in the US and in the world. Coronary artery disease (CAD) is the leading cause of morbidity and mortality. Respiratory diseases are the 3rd and 4th leading causes of death and are frequently complicated by pulmonary vasculopathy and cardiovascular co-morbidities that markedly worsen prognosis. We have learned that infection with SARS-CoV-2 virus damages multiple organs, with cardiovascular, respiratory, and vascular complications. Thus, there is an important need to understand the pathogenesis of cardiopulmonary vascular diseases in order to develop more effective treatments and prevention. The overall goal of the CPVB COBRE program is to facilitate high impact vascular biology research. The CPVB COBRE program provides infrastructure with administrative, pilot project, and two technical cores, thus providing opportunities to expand areas of investigation, experimental and technical approaches, and scientific collaborations. The specific aims of Phase III CPVB COBRE are to: i) award high-impact research projects in the area of cardiopulmonary vascular biology; ii) provide effective and high-quality services in cell isolation and ex vivo organ function (CIOF), mitochondrial function, and in vivo imaging (MF-II); iii) collaborate with IDeA programs in Rhode Island (RI) and other states to foster scientific networks by providing programming, funding, technical services, and resources to enhance research productivity; and iv) maintain a robust line of investigation in vascular biology that meets the needs of the scientific community and furthers research in prevention and treatment of cardiopulmonary vascular diseases. Continuation of the CPVB COBRE into Phase III will sustain the administrative structure for seminars and workshop planning, engagement, and professional development support of investigators, and expertise in cell isolation and ex vivo organ function, mitochondrial function, and in vivo imaging. We will expand and enrich the vascular biology research community by promoting new collaborations and engaging scientists new to the field from a variety of disciplines. At the end of Phase III, we expect to transition to a sustainable CPVB Center serving as a home to the CVPB research community with high quality core services, significant institutional support, and commitment to continue the development of effective approaches to combat or resolve cardiopulmonary vascular diseases.

心肺血管生物学 (CPVB) COBRE 计划的愿景是开发有效的方法 通过更好地预防和治疗影响肺和心血管系统的血管疾病 了解疾病机制。这将通过作为一个跨学科中心来实现， 促进合作研究，并为研究人员提供优秀的技术支持和资源。这 CPVB COBRE 计划的总体使命是建设人力和技术基础设施， 作为增加该州 CPVB 研究的催化剂的服务。心血管和肺部疾病 是美国乃至全世界发病和死亡的主要原因之一。冠状动脉疾病 (CAD) 是发病和死亡的主要原因。呼吸系统疾病是第三和第四大病因 死亡，并且经常并发肺血管病和心血管并发症， 预后明显恶化。我们了解到，感染 SARS-CoV-2 病毒会损害多个器官， 伴有心血管、呼吸系统和血管并发症。因此，非常有必要了解 研究心肺血管疾病的发病机制，以开发更有效的治疗方法 预防。 CPVB COBRE 计划的总体目标是促进高影响力的血管生物学研究。 CPVB COBRE 计划提供具有行政、试点项目和两个技术核心的基础设施， 从而提供扩大研究领域、实验和技术方法的机会，以及 科学合作。第三阶段 CPVB COBRE 的具体目标是： i) 奖励高影响力的研究 心肺血管生物学领域的项目； ii) 提供有效、优质的小区服务 分离和离体器官功能（CIOF）、线粒体功能和体内成像（MF-II）； iii) 协作 与罗德岛州 (RI) 和其他州的 IDeA 项目合作，通过提供编程来培育科学网络， 提高研究生产力的资金、技术服务和资源； iv) 维持稳健的生产线 满足科学界需求并进一步研究血管生物学的研究 预防和治疗心肺血管疾病。 CPVB COBRE 继续进入阶段 III 将维持研讨会和讲习班规划、参与和专业的行政结构 研究人员的开发支持，以及细胞分离和离体器官功能、线粒体方面的专业知识 功能和体内成像。我们将通过促进血管生物学研究社区的扩大和丰富 新的合作以及吸引来自不同学科领域的新科学家。在第三阶段结束时， 我们期望过渡到一个可持续的 CPVB 中心，作为 CVPB 研究社区的家园 高质量的核心服务、重要的机构支持以及对继续发展的承诺 对抗或解决心肺血管疾病的有效方法。